FIGURE 1

Mean Change From Baseline in LogMAR Visual Acuity Score

## (Overall Analysis)

FIGURE 2

Preservation of Vision (< 3 logMAR line Decrease) at Month 6

## (Overall Analysis)

p=.0799 (15 mg vs. Placebo)

FIGURE 3

Preservation of Vision (< 3 logMAR line Decrease) at Month 6

(Subgroup Analysis of Predominantly Classic Lesions)

p=.0209 (15 mg vs. Placebo)

Month 6

# FIGURE 4

Patients With ≥2 logMAR Line Improvement in Vision at Month 6

(Overall Analysis)

p=.025 (15 mg vs. Placebo)

FIGURE 5

## Percent Change from Baseline in Lesion Sizes
Total Lesion (mm^2)

p=.0005 (15 mg vs. Placebo)

Months

- - -◇- - - Anec Acet 30 mg ——■—— Anec Acet 15 mg
- - -○- - - Anec Acet 3 mg ——▲—— Placebo

CNV Component (mm^2)

p<.0001 (15 mg vs. Placebo)

Months

- - -◇- - - Anec Acet 30 mg ——■—— Anec Acet 15 mg
- - -○- - - Anec Acet 3 mg ——▲—— Placebo

Classic Component (mm^2)

p=.0008 (15 mg vs. Placebo)

Months

- - -◇- - - Anec Acet 30 mg ——■—— Anec Acet 15 mg
- - -○- - - Anec Acet 3 mg ——▲—— Placebo